$52.470
+1.291 (+2.46%)收盘时
PBH 资讯
PBH 事件
Company Reports Q1 Revenue of $265.7M, Exceeding Expectations
Reports Q1 revenue $265.7M, consensus $250.32M. "Q1 performance exceeded our sales and earnings expectations, helped by strength across multiple categories that more than offset a challenging consumer backdrop and Clear Eyes variability. We were also pleased to close the Breathe Right acquisition late in the quarter, which added an incremental $6M in revenue and is positioned well for long-term growth. These strong business results generated robust record adjusted free cash flow in the first quarter, leaving us well positioned to rapidly deleverage in the quarters ahead," said CEO Ron Lombardi.
Prestige Consumer Shares Drop 14% to $44.56
Prestige Consumer is down -14.0%, or -$7.25 to $44.56.
Company to Acquire LaCorium Health for Approximately $150M
The company is also announcing a definitive agreement to acquire LaCorium Health for approximately $150M in cash. The transaction, subject to customary conditions, is expected to close in second quarter fiscal 2027. LaCorium generated approximately $40M in trailing twelve months revenue through February 28 and is expected to generate approximately $12M in EBITDA including the benefits from anticipated synergies once the business is fully integrated. LaCorium expects double-digit net sales growth in calendar 2026.
Company Reports Q4 Revenue of $281.62M, Below Consensus
Reports Q4 revenue $281.62M, consensus $293.59M. The company said, "Our fiscal 2026 demonstrated the resilience of our business model in a challenging consumer backdrop. Our diversified portfolio of leading brands with deep consumer heritage supports a durable financial profile and drives strong, growing free cash flow. In fiscal 2026, this resulted in $246.4 million of free cash flow driven by continued strength that included strong growth for Fleet, Dramamine, and Hydralyte in our Gastrointestinal category, which helped partially offset the impacts of limited eye care production as well as fourth quarter shipping disruptions in the Middle East."
Prestige Consumer Healthcare Acquires Breathe Right Brand for $1.045B
Prestige Consumer Healthcare has entered into a definitive agreement to acquire the Breathe Right brand and certain other brands from Foundation Consumer Healthcare for $1.045B, or approximately $900M net of anticipated tax benefits valued at $150M. The company said, "Breathe Right, created in the 1990s, is an iconic #1 brand synonymous with the nasal strip category and represents expansion into a new category for Prestige. Its drug-free nasal strips serve multiple consumer "better breathing" needs, such as sleep wellness, snoring, athletic performance, allergy relief, congestion relief and more. The brand is widely distributed throughout the United States, where it holds the leading position in the category, and is sold internationally, mainly concentrated in Europe, with further growth opportunity. The acquired portfolio also includes other established brands with loyal consumer followings, such as Dimetapp, the #1 most trusted children's cough and cold relief brand by pharmacists." Financial Highlights: Attractive financial profile, with approximately $200M of revenue and approximately $95M of EBITDA over the twelve months ended December 31, 2025; Breathe Right represents approximately two-thirds of the acquired portfolio's revenue and profitability and will be the largest brand in Prestige's portfolio; Remaining portfolio is highlighted by Dimetapp and Anbesol, two long-standing brands in the children's cold relief and oral pain relief categories, respectively; Reinforces Prestige's long-term organic sales growth target of 2-3%; Immediately accretive to Prestige's gross and EBITDA margins; Attractive valuation of 11.0x EBITDA, or approximately 9.5x EBITDA net of anticipated tax benefits, reflecting the benefit of the $150M estimated present value of future tax savings; Expected pro-forma bank-defined net leverage of approximately 4.0x at closing, and a clear path to return to below 3.0x net leverage in fiscal 2028 driven by strong free cash flow generation. The Company plans to finance the acquisition with cash on hand and a new Term Loan credit facility. The transaction is expected to close during the first half fiscal 2027, subject to certain closing conditions, including clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。